Cargando…
Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders
Inborn errors of mitochondrial fatty acid oxidation (FAO) comprise the most common group of disorders identified through expanded newborn screening mandated in all 50 states in the United States, affecting 1:10,000 newborns. While some of the morbidity in FAO disorders (FAODs) can be reduced if iden...
Autores principales: | Sklirou, Evgenia, Alodaib, Ahmad N., Dobrowolski, Steven F., Mohsen, Al-Walid A., Vockley, Jerry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875087/ https://www.ncbi.nlm.nih.gov/pubmed/33584796 http://dx.doi.org/10.3389/fgene.2020.598760 |
Ejemplares similares
-
Effects of triheptanoin (UX007) in patients with long‐chain fatty acid oxidation disorders: Results from an open‐label, long‐term extension study
por: Vockley, Jerry, et al.
Publicado: (2020) -
Dietary management and major clinical events in patients with longchain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study
por: Vockley, Jerry, et al.
Publicado: (2020) -
Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders
por: Zöggeler, Thomas, et al.
Publicado: (2021) -
The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long‐Chain Fatty Acid Oxidation Disorders
por: Lee, Sun Ku, et al.
Publicado: (2021) -
Anaplerotic Triheptanoin Diet Enhances Mitochondrial Substrate Use to Remodel the Metabolome and Improve Lifespan, Motor Function, and Sociability in MeCP2-Null Mice
por: Park, Min Jung, et al.
Publicado: (2014)